GREENWICH LIFESCIENCES INC (GLSI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:GLSI • US3968791083

27.2 USD
-0.82 (-2.93%)
Last: Feb 4, 2026, 11:14 AM
Fundamental Rating

2

GLSI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for GLSI as it has an excellent financial health rating, but there are worries on the profitability. GLSI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year GLSI has reported negative net income.
  • GLSI had a negative operating cash flow in the past year.
  • GLSI had negative earnings in each of the past 5 years.
  • GLSI had a negative operating cash flow in each of the past 5 years.
GLSI Yearly Net Income VS EBIT VS OCF VS FCFGLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • GLSI's Return On Assets of -511.58% is on the low side compared to the rest of the industry. GLSI is outperformed by 93.89% of its industry peers.
  • Looking at the Return On Equity, with a value of -891.34%, GLSI is doing worse than 78.44% of the companies in the same industry.
Industry RankSector Rank
ROA -511.58%
ROE -891.34%
ROIC N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
GLSI Yearly ROA, ROE, ROICGLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

  • GLSI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLSI Yearly Profit, Operating, Gross MarginsGLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, GLSI has more shares outstanding
  • GLSI has more shares outstanding than it did 5 years ago.
  • GLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLSI Yearly Shares OutstandingGLSI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GLSI Yearly Total Debt VS Total AssetsGLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • An Altman-Z score of 98.76 indicates that GLSI is not in any danger for bankruptcy at the moment.
  • GLSI has a Altman-Z score of 98.76. This is amongst the best in the industry. GLSI outperforms 98.66% of its industry peers.
  • GLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 98.76
ROIC/WACCN/A
WACCN/A
GLSI Yearly LT Debt VS Equity VS FCFGLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • GLSI has a Current Ratio of 2.35. This indicates that GLSI is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.35, GLSI is not doing good in the industry: 71.76% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.35 indicates that GLSI has no problem at all paying its short term obligations.
  • GLSI has a worse Quick ratio (2.35) than 69.66% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.35
GLSI Yearly Current Assets VS Current LiabilitesGLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

  • The earnings per share for GLSI have decreased strongly by -82.50% in the last year.
EPS 1Y (TTM)-82.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -7.71% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.25%
EPS Next 2Y-7.52%
EPS Next 3Y-7.71%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLSI Yearly Revenue VS EstimatesGLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2M 4M 6M 8M
GLSI Yearly EPS VS EstimatesGLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GLSI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLSI Price Earnings VS Forward Price EarningsGLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLSI Per share dataGLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A cheap valuation may be justified as GLSI's earnings are expected to decrease with -7.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.52%
EPS Next 3Y-7.71%

More info and screens

0

5. Dividend

5.1 Amount

  • GLSI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GREENWICH LIFESCIENCES INC

NASDAQ:GLSI (2/4/2026, 11:14:38 AM)

27.2

-0.82 (-2.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)04-13
Inst Owners9.51%
Inst Owner Change1.42%
Ins Owners52.53%
Ins Owner Change0.46%
Market Cap376.72M
Revenue(TTM)N/A
Net Income(TTM)-19.48M
Analysts82.5
Price Target48.45 (78.13%)
Short Float %23.5%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.12%
Min EPS beat(2)-22.55%
Max EPS beat(2)0.3%
EPS beat(4)1
Avg EPS beat(4)-52.29%
Min EPS beat(4)-184.78%
Max EPS beat(4)0.3%
EPS beat(8)4
Avg EPS beat(8)-24.58%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.1%
PT rev (3m)13.1%
EPS NQ rev (1m)5.88%
EPS NQ rev (3m)-12.28%
EPS NY rev (1m)-5.02%
EPS NY rev (3m)-5.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 172.41
P/tB 172.41
EV/EBITDA N/A
EPS(TTM)-1.46
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -511.58%
ROE -891.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 2.35
Altman-Z 98.76
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y2.25%
EPS Next 2Y-7.52%
EPS Next 3Y-7.71%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-81.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.37%
OCF growth 3YN/A
OCF growth 5YN/A

GREENWICH LIFESCIENCES INC / GLSI FAQ

What is the fundamental rating for GLSI stock?

ChartMill assigns a fundamental rating of 2 / 10 to GLSI.


Can you provide the valuation status for GREENWICH LIFESCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to GREENWICH LIFESCIENCES INC (GLSI). This can be considered as Overvalued.


What is the profitability of GLSI stock?

GREENWICH LIFESCIENCES INC (GLSI) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for GLSI stock?

The Earnings per Share (EPS) of GREENWICH LIFESCIENCES INC (GLSI) is expected to grow by 2.25% in the next year.